Cyclical intravenous clodronate in postmenopausal osteoporosis: Results of a long-term clinical trial

Bone

Volumn 18, Issue 2, 1996, Pages 179-184

  Filipponi, Paolo ^b   Cristallini, S ^c   Rizzello, E ^c   Policani, G ^c   Fedeli, L ^a   Gregorio, F ^c   Boldrini, S ^c   Troiani, S ^c   Massoni, C ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b POLICLINICO MONTELUCE   (Italy)

^c NONE

Author keywords

Bisphosponates; Bone mineral density; Clodronate; Cyclical therapy; Osteoporosis; Vertebral fractures

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RETROSPECTIVE STUDY; URTICARIA; VERTEBRA FRACTURE;

EID: 0029938003     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/8756-3282(95)00442-4     Document Type: Article

References (30)

1. Amman, P., Rizzoli, R., Caverzasio, J., Shigematsu, T., Slosman, D., and Bonjour, J.-P. Effect of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density. J Bone Miner Res 8:1491-1498; 1993.
2. Bijovoet, O. L. M., Valkema, R., Löwik, C. W. G. M., and Papapoulos, S. E. Bisphosponates in osteoporosis? Osteoporosis Int 3(suppl. 1):230-236; 1993.
3. Boonekamp, P. M., Van der Wee-Pal, L. J. A., Van Wij-van Lennep, M. L. L., Thesing, C. W., and Bijvoet, O. L. M. Two modes of action of bisphosphonates on osteoclastic resorption of mineralised matrix. Bone Miner 1:27-39; 1986.
4. Chesnut, C. H. Synthetic salmon calcitonin, diphosphonates and anabolic steroids in the treatment of postmenopausal osteoporosis. Christiansen, C., Arnaud, C. D., Nordin, B E. C., Parfitt, A. M., Peck, W. A., and Riggs, B. L., Eds. Osteoporosis. Proceedings of the Copenhagen International Symposium on Osteoporosis. Glostrup, Copenhagen: Aalborg Stiftsbogtrykkeri; 1984; 549, 555.
5. Christiansen, C. Prevention and treatment of osteoporosis: a review of current modalities. Bone 13:S35-S40; 1992.
6. Devogelaer, J. P. and Nagant de Deuxchaisnes, C. Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate); non-linear increase of lumbar bone mineral density. J Bone Miner Res 5(suppl. 12):251; 1990.
7. Filipponi, P., Pedetti, M., Fedeli, L., Cini, L., Palumbo, R., Boldrini, S., Massoni, C., and Cristallini, S. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 10:697-703; 1995.
8. Fleisch, H. Bisphosphonates: mechanisms of action and clinical applications. Bone Miner Res 1:319-357; 1983.
9. Fleisch, H. Osteoporosis. Treatment with bisphosphonates: Preclinical studies. Fleisch, H., Ed. Bisphosphonates in bone disease. From the laboratory to the patient Berne: Stämpfli; 1993; 101, 117.
10. Giannini, S., D'Angelo, A., Malvasi, L., Castrignano, R., Pati, T., Tronca, R., Liberto, L., Nobile, M., and Crepaldi, G. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14:137-141; 1993.
11. Hasling, C., Charles, P., Tagehoj Jensen, F., and Mosekilde, L. A comparison of the effects of oestrogen/progesteron, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis. Osteopor Int 4:191-203; 1994.
12. Kanis, J. A. Treatment of osteoporotic fracture. Lancet i:27-33; 1984.
13. Kanis, J. A., Caulin, F., and Russel, R. G. G. Problems in the design of clinical trials in osteoporosis. St. J. Dixon, A., Russel, R. G. G., and Stamp, T. C. B., Eds. Osteoporosis: A multidisciplinary problem. Royal Society of Medicine. International Congress Symposium Series 55:1983; 205, 222.
14. Kanis, J. A., Gertz, B. J., Singer, F., and Ortolani, S. Rationale for the use of alendronate in osteoporosis. Osteopor Int 5:1-13; 1995.
15. Kanis, J. A. and McCloskey, E. V. The use of clodronate in disorders of calcium and skeletal metabolism. Prog Basic Clin Pharmacol 4:89-136; 1990.
16. Kanis, J. A., McCloskey, E. V., Sirtori, P., Khan, S., Fern, D., Eyres, K., Aaron, J., and Beneton, M. N. C. Rationale for the use of clodronate in osteoporosis. Osteopor Int 3(suppl 2):23-28; 1993.
17. Lindsay, R., Cosman, F., and Nieves, J. Estrogen: Effects and actions in osteoporosis. Osteopor Int 3(suppl. 1):S150-S152; 1993.
18. Lombardi, A. and Santora, A. C. Clinical trials with bisphosphonates. Bone Miner 22(suppl.):S59-S70; 1993.
19. McCloskey, E. V., Beneton, M. N. C., O'Rourke, N., Eyres, K., O'Doherty, D., and Kanis, J. A. The effect of phosphate and intermittent clodronate in postmenopausal osteoporosis. Christiansen, C. and Overgaard, K., Eds. Osteoporosis 1990. Copenhagen: Osteopress; 1990; 1401, 1402.
20. Minaire, P., Depassio, J., Bernard, E., Meunier, P. J., Edouard, C., and Pilonchery, G. Effects of clodronate on immobilisation bone loss. Bone 8(suppl.):63-68; 1987.
21. Palmerini, C. A., Fini, C., Florida, A., Morelli, A., and Vedovelli, A. High-performance liquid chromatographic analysis of free hydroxyproline and proline in blood plasma and free and peptide-bound hydroxyproline in urine. J Chromatogr 339:89-94; 1985.
22. Papapoulos, S. E., Landman, J. O., Bijvoet, O. L. M., Löwik, G. M., Valkema, R., Pouwels, E. K. J., and Vermeij, P. The use of bisphosphonates in the treatment of osteoporosis. Bone 13(suppl. 1):41-49; 1992.
23. Parfitt, A. M. The coupling of bone formation to bone resorption. A critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Rel Res 4:1-6; 1982.
24. Parfitt, A. M. Trabecular bone architecture in the pathogenesis and prevention of fracture. Am J Med 82:68-72; 1987.
25. Ross, P., Davis, J., Vagel, J., and Wasnish, R. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int 46:149-161; 1990.
26. Stephan, J. J., Pospichal, J., and Presl, J. Bone loss and biomechanical indices of bone remodelling in surgically induced postmenopausal women. Bone 8:279-284; 1987.
27. Storm, T., Steiniche, T., Thamsborg, G., and Melsen, F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8:199-208; 1993.
28. Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., and Sörensen, O. H. N. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271; 1990.
29. Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R., and Miller, P. D. Intermittent cyclical etidronate treatment in postmenopausal osteoporosis. N Engl J Med 323:73-79; 1990.
30. Yates, A. J. P., Jones, T. H., Mundy, K. I., Hague, R. V., Brown, C. B. Guilland-Cumming, D., and Kanis, J. A. Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J 289:1111-1112; 1984.